EMBL Ventures
VC Fund
Heidelberg, Germany
EMBL Ventures is a German venture capital engaged in the financing and development of products and technologies in the healthcare sector. EMBL Ventures manages three Funds with a total of 120m capital on behalf of major European private and institutional investors. We prefer a role as lead or co-lead investor in financing rounds which typically range from 5m to 40m. Our total commitment in a single portfolio company can go as high as 10m. As with our portfolio companies each Partner at EMBL Ventures strives to build long-lasting personal relationships with Investors in our Funds, such as institutionals, high net-worth individuals and family offices. These relationships are based on EMBL Ventures' core values of open and prompt communication coupled with the ambition to generate maximum return.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $54M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries EMBL Ventures invests in
Stages EMBL Ventures invests in
Countries EMBL Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.3M–$16M
- Series B
- $21M–$70M
Investment Focus
Industry
- Biotechnology 9 (56%)
- Health Care 5 (31%)
- Medical 4 (25%)
- Therapeutics 4 (25%)
- Chemical 1 (6%)
Stage
- Series A 7 (44%)
- Series B 3 (19%)
- Series C 1 (6%)
- Series D 1 (6%)
Country
- Germany 5 (31%)
- Austria 2 (13%)
- Ireland 1 (6%)
- United Kingdom 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jan Adams
Founding Partner
|
Founding Partner | Total investments: 1 | Find email | |
Christoph Antz
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
|
John Arnold
Manager
|
Manager | Total investments: 0 | Find email | |
|
Jorge Galera Garcia Montes
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
|
Stefan Herr
Managing Director
|
Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. | $21.4M / Series B / Jul 29, 2021 | ||
| Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. | $25.9M / Series B / Oct 19, 2020 | ||
| Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $70M / Series B / Apr 30, 2018 | ||
| Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH). | $45.5M / Series D / Apr 26, 2017 | ||
| Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniquesof widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration. | $8.5M / Series A / Jan 12, 2017 | ||
| Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emergingresistance mechanisms of certain hard-to-treat bacteria. These resistance mechanisms are often found in hospital-acquired Gram-negative bacterial infections, and are of particular concern to doctors, healthcare providers, to patients and their families and to governments around the world. Allecra Therapeutics is situated in the BioValley Life Sciences region in the Upper Rhein valley whichencompasses northwest Switzerland, southwestern Germany and the Alsace region of France | $24.8M / Series B / Jun 15, 2016 | ||
| Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund. | $15.7M / Series A / Mar 22, 2016 | ||
| Luxendo will manufacture and sell advanced Single Plane Illumination Microscopes (SPIM) originally developed at EMBL by Lars Hufnagel and his team. SPIM is a rapidly emerging technology that combines optical sectioning with multiple-view imaging to observe tissues and living organisms with impressive resolution. Unlike the conventional techniquesof widefield and confocal fluorescence microscopy, the light sheet technique illuminates on the region surrounding the focal plane of the detection objective in a twin objective configuration. | $6.9M / Series A / Oct 14, 2015 | ||
| ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinicaltrials in cancer patients. | $4M / Series A / Jun 24, 2015 | ||
| ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany | $9.6M / Series A / Oct 28, 2014 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does EMBL Ventures invest in?
EMBL Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does EMBL Ventures invest in?
EMBL Ventures typically joins rounds of $3.3M–$16M at Series A and $21M–$70M at Series B. These are whole funding-round sizes, not EMBL Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds EMBL Ventures took part in.
How do I contact EMBL Ventures?
Public channels for EMBL Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EMBL Ventures?
The team at EMBL Ventures includes Jan Adams (Founding Partner), Christoph Antz (Managing Partner) and John Arnold (Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
